Side-by-side comparison of AI visibility scores, market position, and capabilities
Cologne Germany premium dog supplement market leader with 350K+ European customers; €14M Iris Ventures/Five Seasons Series A Sep 2023 with Tractive data partnership for measurable supplement efficacy competing with Zesty Paws for European pet health.
Mammaly is a Cologne, Germany-based premium dog supplement company — backed with €14 million in Series A funding in September 2023 co-led by Iris Ventures (consumer specialist) and Five Seasons Ventures (food tech) with participation from pet industry veteran Attila Balogh — providing 350,000+ dog owners across Europe with veterinarian-developed functional supplement treats in 25+ recipes addressing digestion, joint care, dental hygiene, skin health, and relaxation. Germany's market leader for premium dog supplements, Mammaly differentiates from traditional supplement formats (pills, powders) through palatability-optimized functional treat formats that dogs consume willingly — combining clinical effectiveness with taste appeal that drives owner adherence to supplement regimens. In 2025, Mammaly announced a strategic partnership with Tractive (world's leading smart pet tracker) to measure supplement effectiveness through objective GPS and vital signs data at scale. Founded in 2020 in Berlin by Stanislav Nazarenus and Alexander Thelen. Certified B Corporation.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.